Alpha-synuclein functions in the nucleus to protect against hydroxyurea-induced replication stress in yeast

Human Molecular Genetics

Volumn 20, Issue 17, 2011, Pages 3401-3414

  Liu, Xianpeng ^a   Lee, Yong Joo ^a   Liou, Liang Chun ^b   Ren, Qun ^b   Zhang, Zhaojie ^b   Wang, Shaoxiao ^a   Witt, Stephan N ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF WYOMING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CHECKPOINT KINASE 2; DNA; GREEN FLUORESCENT PROTEIN; HELICASE; HISTONE H3; HYDROXYUREA; MINICHROMOSOME MAINTENANCE PROTEIN 2; MINICHROMOSOME MAINTENANCE PROTEIN 3; MINICHROMOSOME MAINTENANCE PROTEIN 4; MINICHROMOSOME MAINTENANCE PROTEIN 5; MINICHROMOSOME MAINTENANCE PROTEIN 6; MINICHROMOSOME MAINTENANCE PROTEIN 7; REACTIVE OXYGEN METABOLITE; RED FLUORESCENT PROTEIN; RIBONUCLEOTIDE REDUCTASE;

ANIMAL CELL; ARTICLE; CELL CYCLE S PHASE; CELL NUCLEUS; CELL PROTECTION; CELL STRESS; CHROMATIN; COMPLEX FORMATION; CONTROLLED STUDY; DNA REPLICATION; DRUG MECHANISM; FLUORESCENCE MICROSCOPY; FUNGAL STRAIN; FUNGUS MUTANT; GROWTH INHIBITION; HISTONE ACETYLATION; IMMUNOGOLD LABELING; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING; YEAST;

ALPHA-SYNUCLEIN; CELL NUCLEUS; HYDROXYUREA; RIBONUCLEOTIDE REDUCTASES; SACCHAROMYCES CEREVISIAE;

EID: 80051694263     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr246     Document Type: Article

References (78)

1. Abou-Sleiman, P.M., Healy, D.G. and Wood, N.W. (2004) Causes of Parkinson's disease: genetics of DJ-1. Cell Tissue Res., 318, 185-188.
2. Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S.D. and Giusti, P. (2004) Alph-synuclein and Parkinson's disease. Faseb. J., 18, 617-626.
3. Moore, D.J., West, A.B., Dawson, V.L. and Dawson, T.M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 28, 57-87.
4. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alph-synuclein in Lewy bodies. Nature, 388, 839-840.
5. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the alph-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
6. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding alph-synuclein in Parkinson's disease. Nat. Genet., 18, 106-108.
7. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B. et al. (2004) The new mutation, E46K, of alph-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 55, 164-173.
8. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) alph-synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
9. Karube, H., Sakamoto, M., Arawaka, S., Hara, S., Sato, H., Ren, C.H., Goto, S., Koyama, S., Wada, M., Kawanami, T. et al. (2008) N-terminal region of alph-synuclein is essential for the fatty acid-induced oligomerization of the molecules. FEBS Lett., 582, 3693-3700.
10. Vamvaca, K., Volles, M.J. and Lansbury, P.T. Jr (2009) The first N-terminal amino acids of Alph-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J. Mol. Biol., 389, 413-424.
11. Yamaguchi, Y., Masuda, M., Sasakawa, H., Nonaka, T., Hanashima, S., Hisanaga, S., Kato, K. and Hasegawa, M. (2010) Characterization of inhibitor-bound alph-synuclein dimer: role of Alph-synuclein N-terminal region in dimerization and inhibitor binding. J. Mol. Biol., 395, 445-456.
12. Jensen, P.H., Hojrup, P., Hager, H., Nielsen, M.S., Jacobsen, L., Olesen, O.F., Gliemann, J. and Jakes, R. (1997) Binding of Abeta to alpha- and beta-synucleins: identification of segments in alph-synuclein/NAC precursor that bind Abeta and NAC. Biochem. J., 323, 539-546.
13. Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R. and Sudhof, T.C. (2010) Alph-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science, 329, 1663-1667.
14. Ahn, M., Kim, S., Kang, M., Ryu, Y. and Kim, T.D. (2006) Chaperone-like activities of alph-synuclein: alph-synuclein assists enzyme activities of esterases. Biochem. Biophys. Res. Commun., 346, 1142-1149.
15. Binolfi, A., Lamberto, G.R., Duran, R., Quintanar, L., Bertoncini, C.W., Souza, J.M., Cervenansky, C., Zweckstetter, M., Griesinger, C. and Fernandez, C.O. (2008) Site-specific interactions of Cu(II) with alpha and betαuclein: bridging the molecular gap between metal binding and aggregation. J. Am. Chem. Soc., 130, 11801-11812.
16. Specht, C.G., Tigaret, C.M., Rast, G.F., Thalhammer, A., Rudhard, Y. and Schoepfer, R. (2005) Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol. Cell Neurosci., 28, 326-334.
17. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E. and Lansbury, P.T. Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alph-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA, 97, 571-576.
18. Davidson, W.S., Jonas, A., Clayton, D.F. and George, J.M. (1998) Stabilization of Alph-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem., 273, 9443-9449.
19. Nemani, V.M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M.K., Chaudhry, F.A., Nicoll, R.A. and Edwards, R.H. (2010) Increased expression of Alph-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron, 65, 66-79.
20. Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., Strathearn, K.E., Liu, F. et al. (2006) Alph-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science, 313, 324-328.
21. Lindersson, E., Beedholm, R., Hojrup, P., Moos, T., Gai, W., Hendil, K.B. and Jensen, P.H. (2004) Proteasomal inhibition by alph-synuclein filaments and oligomers. J. Biol. Chem., 279, 12924-12934.
22. Betarbet, R., Sherer, T.B. and Greenamyre, J.T. (2005) Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol., 191, (Suppl. 1), S17-S27.
23. Xu, J., Kao, S.Y., Lee, F.J., Song, W., Jin, L.W. and Yankner, B.A. (2002) Dopamine-dependent neurotoxicity of alph-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med., 8, 600-606.
24. Flower, T.R., Chesnokova, L.S., Froelich, C.A., Dixon, C. and Witt, S.N. (2005) Heat shock prevents Alph-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J. Mol. Biol., 351, 1081-1100.
25. Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T. and Lansbury, P.T. Jr (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature, 418, 291.
26. Volles, M.J. and Lansbury, P.T. Jr (2002) Vesicle permeabilization by protofibrillar Alph-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry, 41, 4595-4602.
27. Manning-Bog, A.B., McCormack, A.L., Purisai, M.G., Bolin, L.M. and Di Monte, D.A. (2003) Alph-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci., 23, 3095-3099.
28. Perez-Sanchez, F., Milan, M., Buendia, P., Cano-Jaimez, M., Ambrosio, S., Rosenthal, A. and Farinas, I. (2010) Prosurvival effect of human wild-type Alph-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice. Neuroscience, 167, 261-276.
29. Cano-Jaimez, M., Perez-Sanchez, F., Milan, M., Buendia, P., Ambrosio, S. and Farinas, I. (2010) Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by Alph-synuclein. Neurobiol. Dis., 38, 92-103.
30. Gorbatyuk, O.S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A.S., Sullivan, L.F., Mandel, R.J., Chen, W., Meyers, C., Manfredsson, F.P. et al. (2010) In vivo RNAi-mediated alph-synuclein silencing induces nigrostriatal degeneration. Mol. Ther., 18, 1450-1457.
31. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O.M. and Sudhof, T.C. (2005) Alph-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell, 123, 383-396.
32. Bayir, H., Kapralov, A.A., Jiang, J., Huang, Z., Tyurina, Y.Y., Tyurin, V.A., Zhao, Q., Belikova, N.A., Vlasova, I.I., Maeda, A. et al. (2009) Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease. J. Biol. Chem., 284, 15951-15969.
33. Davies, P., Moualla, D. and Brown, D.R. (2011) Alph-synuclein is a cellular ferrireductase. PLoS ONE, 6, e15814.
34. Outeiro, T.F. and Lindquist, S. (2003) Yeast cells provide insight into alph-synuclein biology and pathobiology. Science, 302, 1772-1775.
35. Roberts, R.L., Mosch, H.U. and Fink, G.R. (1997) 14-3-3 proteins are essential for RAS/MAPK cascade signaling during pseudohyphal development in S. cerevisiae. Cell, 89, 1055-1065.
36. Dowell, R.D., Ryan, O., Jansen, A., Cheung, D., Agarwala, S., Danford, T., Bernstein, D.A., Rolfe, P.A., Heisler, L.E., Chin, B. et al. (2010) Genotype to phenotype: a complex problem. Science, 328, 469.
37. Kontopoulos, E., Parvin, J.D. and Feany, M.B. (2006) {alpha}-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet., 15, 3012-3023.
38. Tatchell, K., Makrantoni, V., Stark, M.J. and Robinson, L.C. (2011) Temperature-sensitive ipl1-2/Aurora B mutation is suppressed by mutations in TOR complex 1 via the Glc7/PP1 phosphatase. Proc. Natl Acad. Sci. USA, 108, 3994-3999.
39. Goers, J., Manning-Bog, A.B., McCormack, A.L., Millett, I.S., Doniach, S., Di Monte, D.A., Uversky, V.N. and Fink, A.L. (2003) Nuclear localization of alph-synuclein and its interaction with histones. Biochemistry, 42, 8465-8471.
40. Ramanathan, B. and Smerdon, M.J. (1986) Changes in nuclear protein acetylation in u.v.-damaged human cells. Carcinogenesis, 7, 1087-1094.
41. Howe, L., Auston, D., Grant, P., John, S., Cook, R.G., Workman, J.L. and Pillus, L. (2001) Histone H3 specific acetyltransferases are essential for cell cycle progression. Genes Dev., 15, 3144-3154.
42. Elledge, S.J. (1996) Cell cycle checkpoints: preventing an identity crisis. Science, 274, 1664-1672.
43. Lopes, M., Cotta-Ramusino, C., Pellicioli, A., Liberi, G., Plevani, P., Muzi-Falconi, M., Newlon, C.S. and Foiani, M. (2001) The DNA replication checkpoint response stabilizes stalled replication forks. Nature, 412, 557-561.
44. Zhao, X., Chabes, A., Domkin, V., Thelander, L. and Rothstein, R. (2001) The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/ Rad53 kinase cascade during growth and in response to DNA damage. EMBO J., 20, 3544-3553.
45. Andreson, B.L., Gupta, A., Georgieva, B.P. and Rothstein, R. (2010) The ribonucleotide reductase inhibitor, Sml1, is sequentially phosphorylated, ubiquitylated and degraded in response to DNA damage. Nucleic Acids Res., 38, 6490-6501.
46. Fasullo, M. and Sun, M. (2008) The Saccharomyces cerevisiae checkpoint genes RAD9, CHK1 and PDS1 are required for elevated homologous recombination in a mec1 (ATR) hypomorphic mutant. Cell Cycle, 7, 2418-2426.
47. Ge, X.Q., Jackson, D.A. and Blow, J.J. (2007) Dormant origins licensed by excess Mcm2-7 are required for human cells to survive replicative stress. Genes Dev., 21, 3331-3341.
48. Ibarra, A., Schwob, E. and Mendez, J. (2008) Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc. Natl Acad. Sci. USA, 105, 8956-8961.
49. Segurado, M. and Tercero, J.A. (2009) The S-phase checkpoint: targeting the replication fork. Biol. Cell, 101, 617-627.
50. Woodward, A.M., Gohler, T., Luciani, M.G., Oehlmann, M., Ge, X., Gartner, A., Jackson, D.A. and Blow, J.J. (2006) Excess Mcm2-7 license dormant origins of replication that can be used under conditions of replicative stress. J. Cell Biol., 173, 673-683.
51. Driscoll, R., Hudson, A. and Jackson, S.P. (2007) Yeast Rtt109 promotes genome stability by acetylating histone H3 on lysine 56. Science, 315, 649-652.
52. Han, J., Zhou, H., Li, Z., Xu, R.M. and Zhang, Z. (2007) The Rtt109-Vps75 histone acetyltransferase complex acetylates non-nucleosomal histone H3. J. Biol. Chem., 282, 14158-14164.
53. Koch, C., Moll, T., Neuberg, M., Ahorn, H. and Nasmyth, K. (1993) A role for the transcription factors Mbp1 and Swi4 in progression from G1 to S phase. Science, 261, 1551-1557.
54. Mulder, K.W., Winkler, G.S. and Timmers, H.T. (2005) DNA damage and replication stress induced transcription of RNR genes is dependent on the Ccr4-Not complex. Nucleic Acids Res., 33, 6384-6392.
55. Mimura, S., Komata, M., Kishi, T., Shirahige, K. and Kamura, T. (2009) SCF(Dia2) regulates DNA replication forks during S-phase in budding yeast. EMBO J., 28, 3693-3705.
56. Haworth, J., Alver, R.C., Anderson, M. and Bielinsky, A.K. (2010) Ubc4 and Not4 regulate steady-state levels of DNA polymerase-alpha to promote efficient and accurate DNA replication. Mol. Biol. Cell, 21, 3205-3219.
57. Bollenbach, T. and Kishony, R. (2009) Hydroxyurea triggers cellular responses that actively cause bacterial cell death. Mol. Cell, 36, 728-729.
58. Davies, B.W., Kohanski, M.A., Simmons, L.A., Winkler, J.A., Collins, J.J. and Walker, G.C. (2009) Hydroxyurea induces hydroxyl radical-mediated cell death in Escherichia coli. Mol. Cell, 36, 845-860.
59. Marchetti, M.A., Weinberger, M., Murakami, Y., Burhans, W.C. and Huberman, J.A. (2006) Production of reactive oxygen species in response to replication stress and inappropriate mitosis in fission yeast. J. Cell Sci., 119, 124-131.
60. Habig, K., Walter, M., Stappert, H., Riess, O. and Bonin, M. (2009) Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA-a key player in the pathogenesis of Parkinson's disease. Brain Res., 1256, 19-33.
61. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V. and Greenamyre, J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 3, 1301-1306.
62. Tanner, C.M., Kamel, F., Ross, G.W., Hoppin, J.A., Goldman, S.M., Korell, M., Marras, C., Bhudhikanok, G.S., Kasten, M., Chade, A.R. et al. (2011) Rotenone, Paraquat and Parkinson's Disease. Environ. Health Perspect, 119, 866-872. doi: 10.1289/ehp.1002839.
63. Smith, W.W., Jiang, H., Pei, Z., Tanaka, Y., Morita, H., Sawa, A., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2005) Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alph-synuclein-induced toxicity. Hum. Mol. Genet., 14, 3801-3811.
64. Ulmer, T.S., Bax, A., Cole, N.B. and Nussbaum, R.L. (2005) Structure and dynamics of micelle-bound human alph-synuclein. J. Biol. Chem., 280, 9595-9603.
65. Volles, M.J. and Lansbury, P.T. Jr (2003) Zeroing in on the pathogenic form of alph-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry, 42, 7871-7878.
66. Davies, P., Wang, X., Sarell, C.J., Drewett, A., Marken, F., Viles, J.H. and Brown, D.R. (2010) The synucleins are a family of redox-active copper binding proteins. Biochemistry, 50, 37-47.
67. Lucas, H.R. and Lee, J.C. (2011) Copper(ii) enhances membrane-bound alph-synuclein helix formation. Metallomics, 3, 280-283.
68. Levin, V.A., Rodriguez, L.A., Edwards, M.S., Wara, W., Liu, H.C., Fulton, D., Davis, R.L., Wilson, C.B. and Silver, P. (1988) Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. J. Neurosurg., 68, 383-387.
69. Eckman, J.R. (2010) Hydroxyurea enhances sickle survival. Blood, 115, 2331-2332.
70. Burke, D., Dawson, D. and Stearns, T. (2000) Methods in Yeast Genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
71. Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
72. Kessler, J.C., Rochet, J.C. and Lansbury, P.T. Jr (2003) The N-terminal repeat domain of Alph-synuclein inhibits beta-sheet and amyloid fibril formation. Biochemistry, 42, 672-678.
73. Edgington, N.P. and Futcher, B. (2001) Relationship between the function and the location of G1 cyclins in S. cerevisiae. J. Cell Sci., 114, 4599-4611.
74. Flower, T.R., Clark-Dixon, C., Metoyer, C., Yang, H., Shi, R., Zhang, Z. and Witt, S.N. (2007) YGR198w (YPP1) targets A30P alph-synuclein to the vacuole for degradation. J. Cell Biol., 177, 1091-1104.
75. Jakubowski, W. and Bartosz, G. (1997) Estimation of oxidative stress in Saccharomyces cerevisae with fluorescent probes. Int. J. Biochem. Cell Biol., 29, 1297-1301.
76. Zheng, K., Pan, J.W., Ye, L., Fu, Y., Peng, H.Z., Wan, B.Y., Gu, Q., Bian, H.W., Han, N., Wang, J.H. et al. (2007) Programmed cell death-involved aluminum toxicity in yeast alleviated by antiapoptotic members with decreased calcium signals. Plant Physiol., 143, 38-49.
77. Bergersen, L.H., Storm-Mathisen, J. and Gundersen, V. (2008) Immunogold quantification of amino acids and proteins in complex subcellular compartments. Nat. Protoc., 3, 144-152.
78. Zhao, X., Georgieva, B., Chabes, A., Domkin, V., Ippel, J.H., Schleucher, J., Wijmenga, S., Thelander, L. and Rothstein, R. (2000) Mutational and structural analyses of the ribonucleotide reductase inhibitor Sml1 define its Rnr1 interaction domain whose inactivation allows suppression of mec1 and rad53 lethality. Mol. Cell Biol., 20, 9076-9083.